HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity
NCT ID: NCT01377909
Last Updated: 2013-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
20 participants
INTERVENTIONAL
2012-03-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Design: Twenty poor responders to prior PIFN/RBV will be given 48 weeks of statin monotherapy. Veterans and civilians between the ages of 18 and 70 are eligible.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C
NCT00814606
Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin
NCT00487318
Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients
NCT00803309
Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
NCT00056862
Fluvastatin Versus Hepatitis C Virus
NCT00441493
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
statin
statin
daily statin orally for 48 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
statin
daily statin orally for 48 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* severe cardiac disease (ejection fraction \< 20% or uncontrolled angina)
* unexplained muscle pain at time of screening
* pregnancy
* renal insufficiency (creatine clearance \< 50 ml/min)
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bader, Ted, M.D.
INDIV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ted Bader, MD
Director of Liver Diseases, Professor, Department of Medicine, Section of Gastroenterology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ted Bader, M.D.
Role: PRINCIPAL_INVESTIGATOR
VA Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Veterans Administration Medical Center (VAMC)
Oklahoma City, Oklahoma, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Bader 15859
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.